Circassia Pharmaceuticals Dividends - CIR

Circassia Pharmaceuticals Dividends - CIR

Best deals to access real time data!
Level 2 Basic
Monthly Subscription
for only
Monthly Subscription
for only
UK/US Silver
Monthly Subscription
for only
VAT not included
Stock Name Stock Symbol Market Stock Type Stock ISIN Stock Description
Circassia Pharmaceuticals Plc CIR London Ordinary Share GB00BJVD3B28 ORD 0.08P
  Price Change Price Change % Stock Price High Price Low Price Open Price Close Price Last Trade
  0.45 2.81% 16.45 17.25 15.80 16.00 16.00 15:16:10
more quote information »
Industry Sector

Circassia Pharmaceuticals CIR Dividends History

Announcement Date Type Currency Dividend Amount Period Start Period End Ex Date Record Date Payment Date Total Dividend Amount

Top Dividend Posts

the abbot: I think as the latest interview this is well worth watching again, Steve certainly doesn't look like a man worried, indeed I would say he seems very happy with how things are going, all except the share price that is, but then at the time this was recorded I be he knew that woodford were going to be reducing. Circassia sets platform for strong growth in 2019 after period of consolidation [...]
seesawpat: Couldn't agree more Abbot. Share price 18p and they're giving themselves options to buy at 0.008p! Snouts in troughs - they haven't even bothered to tell us what the share performance has to be in order for these to vest.
the abbot: What a load of idiots these directors are, share price on the floor and they are still issuing themselves options, sack the lot of them the useless freeloaders. Think they can hide these with an after hours RNS, idiots
the abbot: Lol there you go again a late sell as the UT to push the share price negative at the end of the day.
pre: so 2 issues here which create uncertainty and may affect share price: 1. woodfords holding of 28% by far the largest...if he sells on the market this could create significant volatility, or will he find another home? 2. Final deferred payment of $100 million is due by 30 June 2019 to Astrazeneca - how are CIR going to raise this? more dilution for shareholders??
aspringo: Not that the attached is overly helpful but asked some question of Circassia and the reply is below. Understand its a standard response but thought they should know we're not happy..The Company is also disappointed with the share price decline, which has occurred despite a number of positive developments in the business announced in recent months.  In terms of the market, both the sector and a number of UK small / mid-cap companies have experienced significant turbulence, which is also likely impacted by wider global concerns.  In terms of managing the business, we announced full year results at the beginning of May, where the Company outlined recent progress and we remain focused on driving the business forward.   Thanks again for your note. Kind regards
ltinvestor: Outside factors may have provided us with an extremely undervalued business.Normally a share price fall is a reflection on how badly a business is trading which does not appear to be the case here.I suspect the companies brokers are looking to place the Woodford holding and may even have started the process with over 30m shares traded yesterday...
turvart: Do CIr have any exposure to UK sales?
badger60: the abbotYep..... unfortunately these days many promising small caps are very poorly marketed and/or become the object of manipulation by nearly everybody (understandably) becomes a trader, and I'm not too good at that.The big money for me is (choosing the right stock) made by being patient. On balance I have done well over the years, but also taken a few chunky hits along the way. Hemogenyx imo is potentially a serious multibagger, but it has been unloved, overlooked and very badly handled by the market since it came in October 2017, and like CIR much of the the embedded value is in no way reflected in the share price or market cap. ......but that's what no pain, no gain is all about.Good luck here....ttfn.
gersemi: 6 hours ago Circassia slashes net cash outflow By Mark Robinson Drug developers require a steady stream of positive clinical updates to underpin market valuations. Circassia Pharmaceuticals (CIE) provided shareholders with precisely that a month ahead of these full-year figures when it revealed that US regulators had given the green light for two of its chronic obstructive pulmonary disease (COPD) treatments. It is too early to say whether the news has arrested the share price decline of the previous 12-months, but given that very few UK-sponsored drugs have been approved in the US in the past few years, so the news - particularly in relation to the Duaklir drug - would not have gone unnoticed amongst the sector heavyweights. The drugs are complementary in that patients using its existing COPD treatment Tudorza (which got the go-ahead for the inclusion of new clinical data on its label) can move on to Duaklir if their condition deteriorates without needing to change their inhaler device. Bloomberg consensus gives revenues of £64.5m for the December 2019 year-end, with an accompanying adjusted earnings loss of 7.6p a share, before £84.8m and a 5.2p loss in the following year. CIRCASSIA PHARMACEUTICALS (CIR) ORD PRICE: 32p MARKET VALUE: £ 120m TOUCH: 31.2-32p 12-MONTH HIGH: 98p LOW: 25p DIVIDEND YIELD: NIL PE RATIO: NA NET ASSET VALUE: 34p* NET CASH: £40.7m Year to 31 Dec Turnover (£m) Pre-tax profit (£m) Earnings per share (p) Dividend per share (p) 2014 nil -44.0 -21 nil 2015 10.8 -62.8 -20 nil 2016 23.1 -38.8 -48 nil 2017 (restated) 46.3 -74.2 -19 nil 2018 48.3 -55.8 -14 nil % change +4 - - - Ex-div: - Payment: - *Includes intangible assets of £231m, or 61.5p a share. IC View Duaklir was initially approved in the European Union five years ago, but the US launch in the second half of 2019 is highly significant given the potential up-scale. With a new revenue stream in prospect, 2018 may come to be seen as a watershed for the company. Though the net cash-outflow fell by two-thirds to £18.8m, the continued backing by AstraZeneca (AZN), which boosted its holding to 19.9 per cent midway through last year, has been crucial. However, given the lowly free-float, shareholders may struggle to buy into the US growth story. Hold. Last IC view: Hold, 34p, 01 Apr 2019 end
Your Recent History
Circassia ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191016 14:32:18